Objective: To compare three year survival, median survival and improved longevity with the addition of doxorubicin to a che­motherapy regimen of cisplatin and cyclophospamide used in the treatment of ovarian cancer and to integrate this with a previous meta-analysis that compared three year survival. Methods: Twenty-three studies that evaluated either the control or test arms were combined for meta-analysis. Five studies were randomized with both arms. Inclusion criteria consisted of median survival data, three year survival data, no previous chemothe­rapy or radiation and adequate follow-up. The data were analyzed with a twotailed t test, a fixed effects odds ratio, a random effects odds ratio, logistic regression modeling for three year survival and standard regression modeling for median survival. Results: A statistically significant improvement in three year survival was demonstrated with the fixed effects odds ratio analy­sis combining the five prospective randomized studies and with logistic regression model of all the studies. Random effects odds ratio and the two-tailed t test failed to show statistical significance. Standard regression modeling demonstrated statistically significant improvement in median survival for a doxorubicin dose intensity of 40 mg/m² and near significance for a doxorubicin dose intensity of 50 mg/m². Median survival was improved by 1.91 months with the addition of doxorubicin to the cisplatin/cyclophosphamide regimen. Conclusion: Although there appears to be statistically significant improvement in three year survival and median survival with the addition of doxorubicin to the cisplatin/cyclophoshamide regimen for ovarian cancer, the actual improvement in median survival is less than two months and therefore, the added toxicity of doxorubicin may not be warranted.